Should I buy or sell Structure Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares. View GPCR analyst ratings or view top-rated stocks .

What is Structure Therapeutics' stock price target for 2024?

6 equities research analysts have issued 1 year target prices for Structure Therapeutics' stock. Their GPCR share price targets range from $65.00 to $97.00. On average, they predict the company's stock price to reach $85.71 in the next twelve months. This suggests a possible upside of 135.7% from the stock's current price. View analysts price targets for GPCR or view top-rated stocks among Wall Street analysts .

How have GPCR shares performed in 2024?

Structure Therapeutics' stock was trading at $40.76 at the beginning of the year. Since then, GPCR stock has decreased by 10.8% and is now trading at $36.36. View the best growth stocks for 2024 here .

Are investors shorting Structure Therapeutics?

Structure Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,740,000 shares, an increase of 15.4% from the March 15th total of 3,240,000 shares. Based on an average daily volume of 584,800 shares, the days-to-cover ratio is currently 6.4 days. Currently, 9.0% of the shares of the company are sold short. View Structure Therapeutics' Short Interest .

When is Structure Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GPCR earnings forecast .

How were Structure Therapeutics' earnings last quarter?

Structure Therapeutics Inc. (NASDAQ:GPCR) announced its earnings results on Friday, March, 8th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04.

What ETFs hold Structure Therapeutics' stock?

ETFs with the largest weight of Structure Therapeutics (NASDAQ:GPCR) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ) . Fidelity Disruptive Medicine ETF (FMED) .

When did Structure Therapeutics IPO?

Structure Therapeutics (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share.

Who are Structure Therapeutics' major shareholders?

Structure Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.10%) and TrueMark Investments LLC (0.06%).

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GPCR

Structure Therapeutics (GPCR) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free GPCR Stock Alerts

$36.36

+0.18 (+0.50%)

(As of 04:00 PM ET)

Compare

Today's Range: $35.70
▼
$37.47
50-Day Range: $33.90
▼
$49.00
52-Week Range: $21.79
▼
$75.02

Volume: 383,323 shs
Average Volume: 576,725 shs
Market Capitalization: $1.69 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $85.71

Get Structure Therapeutics alerts:

Structure Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 135.7% Upside
$85.71 Price Target
Short Interest: Bearish
9.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.87
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.98) to ($0.68) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.65 out of 5 stars

Medical Sector

645th out of 911 stocks

Pharmaceutical Preparations Industry

278th out of 412 stocks

3.5

Analyst's Opinion

Consensus Rating
Structure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Structure Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.03% of the float of Structure Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Structure Therapeutics has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in Structure Therapeutics has recently increased by 15.43%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Structure Therapeutics does not currently pay a dividend.
Dividend Growth
Structure Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GPCR.

2.7

News and Social Media Coverage

News Sentiment
Structure Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Structure Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for GPCR on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Structure Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Structure Therapeutics are expected to grow in the coming year, from ($0.98) to ($0.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Structure Therapeutics is -43.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Structure Therapeutics is -43.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Structure Therapeutics has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

Click here to learn more >>>

About Structure Therapeutics Stock (NASDAQ:GPCR)

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

GPCR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GPCR Stock News Headlines

April 18, 2024 | msn.com

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

April 18, 2024 | theglobeandmail.com

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

April 16, 2024 | finance.yahoo.com

Structure Therapeutics Inc. (GPCR)

April 13, 2024 | americanbankingnews.com

Structure Therapeutics Inc. Expected to Earn FY2024 Earnings of ($1.10) Per Share (NASDAQ:GPCR)

April 12, 2024 | americanbankingnews.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.71 Consensus Price Target from Brokerages

April 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Structure Therapeutics on Upcoming GSBR-1290 Phase 2a Data Optimism

April 10, 2024 | markets.businessinsider.com

Buy Rating for Structure Therapeutics on Strong Obesity Drug Prospects and Strategic Partnerships

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

April 10, 2024 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Now Covered by Analysts at Cantor Fitzgerald

April 9, 2024 | msn.com

Cantor starts Structure at overweight, sees positive data for GLP-1 drug

March 30, 2024 | investorplace.com

7 Small-Cap Stocks that Wall Street Loves for Good Reason

March 20, 2024 | finance.yahoo.com

GPCR Dec 2024 50.000 call

March 17, 2024 | finance.yahoo.com

GPCR Sep 2024 30.000 put

March 16, 2024 | finance.yahoo.com

GPCR May 2024 30.000 put

March 16, 2024 | finance.yahoo.com

GPCR Apr 2024 30.000 put

March 15, 2024 | msn.com

GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023

March 13, 2024 | bizjournals.com

Former CFO sues Peninsula drug company, alleges domestic violence incident led to her firing

March 10, 2024 | finance.yahoo.com

We Think Structure Therapeutics (NASDAQ:GPCR) Can Afford To Drive Business Growth

March 9, 2024 | finance.yahoo.com

GPCR Mar 2024 40.000 put

March 8, 2024 | globenewswire.com

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

March 8, 2024 | globenewswire.com

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Structure Therapeutics Amidst Competitive Landscape and Promising Drug Prospects

February 23, 2024 | benzinga.com

Structure Therapeutics Stock (NASDAQ:GPCR), Short Interest Report

February 23, 2024 | benzinga.com

Structure Therapeutics Stock (NASDAQ:GPCR) Dividends: History, Yield and Dates

February 20, 2024 | ca.finance.yahoo.com

GPCR Mar 2024 60.000 call

February 18, 2024 | seekingalpha.com

Baron Opportunity Fund Q4 2023 Shareholder Letter

See More Headlines

Receive GPCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GPCR
CUSIP: N/A
CIK: 1888886
Web: www.structuretx.com
Phone: 628-229-9277
Fax: N/A
Employees: 93
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $85.71
High Stock Price Target: $97.00
Low Stock Price Target: $65.00
Potential Upside/Downside: +136.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,620,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.69%
Return on Assets: -30.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.14
Quick Ratio: 19.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.77 per share
Price / Book: 3.71

Miscellaneous

Outstanding Shares: 46,600,000
Free Float: N/A
Market Cap: $1.69 billion
Optionable: Optionable
Beta: N/A

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Raymond C. Stevens Ph.D. (Age 60)
CEO & Director
Comp: $747.33k
Dr. Yingli Ma Ph.D. (Age 50)
Chief Technology Officer
Comp: $497.58k
Dr. Mark A. Bach M.D. (Age 67)
Ph.D., Chief Medical Officer
Comp: $628.37k
Mr. Jun S. Yoon (Age 46)
Co- Founder, CFO & Secretary
Dr. Xichen Lin Ph.D. (Age 50)
Chief Scientific Officer
Mr. Tony Peng
Senior Vice President of Legal
Mr. Bob Gatmaitan
Senior Vice President of People
Dr. Hui Lei Ph.D.
Senior Vice President of Chemistry
Dr. Fang Zhang Ph.D.
Executive VP & Head of Biology
Ms. Lani Ibarra
Senior Vice President of Clinical Development Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GPCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Structure Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares.
View GPCR analyst ratings or view top-rated stocks.
What is Structure Therapeutics' stock price target for 2024?: 6 equities research analysts have issued 1 year target prices for Structure Therapeutics' stock. Their GPCR share price targets range from $65.00 to $97.00. On average, they predict the company's stock price to reach $85.71 in the next twelve months. This suggests a possible upside of 135.7% from the stock's current price.
View analysts price targets for GPCR or view top-rated stocks among Wall Street analysts.
How have GPCR shares performed in 2024?: Structure Therapeutics' stock was trading at $40.76 at the beginning of the year. Since then, GPCR stock has decreased by 10.8% and is now trading at $36.36.
View the best growth stocks for 2024 here.
Are investors shorting Structure Therapeutics?: Structure Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,740,000 shares, an increase of 15.4% from the March 15th total of 3,240,000 shares. Based on an average daily volume of 584,800 shares, the days-to-cover ratio is currently 6.4 days. Currently, 9.0% of the shares of the company are sold short.
View Structure Therapeutics' Short Interest.
When is Structure Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GPCR earnings forecast.
How were Structure Therapeutics' earnings last quarter?: Structure Therapeutics Inc. (NASDAQ:GPCR) announced its earnings results on Friday, March, 8th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04.

What ETFs hold Structure Therapeutics' stock?: ETFs with the largest weight of Structure Therapeutics (NASDAQ:GPCR) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ).Fidelity Disruptive Medicine ETF (FMED).
When did Structure Therapeutics IPO?: Structure Therapeutics (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share.
Who are Structure Therapeutics' major shareholders?: Structure Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.10%) and TrueMark Investments LLC (0.06%).
How do I buy shares of Structure Therapeutics?: Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GPCR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Structure Therapeutics (GPCR) Stock Price, News & Analysis

Structure Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Structure Therapeutics Stock (NASDAQ:GPCR)

GPCR Stock Price History

GPCR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

GPCR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™